Abstract
The Coronavirus disease-2019 (COVID-19) pandemic is an unprecedented health care crisis and has led to over 1.5 million deaths worldwide. The risk of severe COVID-19 and mortality is markedly raised in patients with cancer, prompting several collaborative groups to issue guidelines to mitigate the risk of infection by delaying or de-escalating immunosuppressive therapy. However, delayed therapy is often not feasible for patients requiring treatment for acute leukemia or stem cell transplantation. We provide a focused review of the recommendations and evidence for managing this high-risk group of patients while minimizing the risk of COVID-19 infection, and provide a small snapshot of treatment data from our center.
【저자키워드】 Cancer, COVID, Transplant, hematology, Blood, 【초록키워드】 COVID-19, Treatment, pandemic, therapy, Mortality, severe COVID-19, Infection, risk, Health, Patient, death, group, Care, leukemia, Evidence, risk of infection, immunosuppressive, Stem cell transplantation, Patients with cancer, recommendation, mitigate, risk of COVID-19, raised, feasible, 【제목키워드】 review,